復星醫藥(2196.HK)跳空高開14.98% 擁有輝瑞疫苗的國內權益
格隆匯11月10日丨復星醫藥(2196.HK)跳空高開14.98%報37.6港元,盤前成交4130萬港元,最新總市值1422億港元。A股目前集合競價時段漲停。輝瑞公司昨夜宣佈其冠狀病毒疫苗有效率超過90%,遠超預期和FDA上市要求,並計劃在11月的第三週向美FDA提交緊急使用授權,此外預計在2020年將生產5000萬劑疫苗,到2021年將生產多達13億劑疫苗。值得注意的是,復星醫藥持有輝瑞的這款新冠疫苗的相關權益。今年3月的公告顯示,復星醫藥將負責該疫苗在中國內地及港澳台地區的臨牀試驗、上市申請、市場銷售,並承擔相應的成本和費用。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.